ASX:CSLBiotechs
A Look At CSL (ASX:CSL) Valuation As Kankakee Expansion Targets Higher Plasma Therapy Capacity
CSL (ASX:CSL) has started expanding its Kankakee, Illinois manufacturing site. This is a large U.S. project focused on plasma derived and immunoglobulin therapies and it also introduces the company’s Horizon 2 plasma efficiency technology.
See our latest analysis for CSL.
Despite CSL announcing the Kankakee expansion and continuing to present at healthcare conferences, the share price is A$138.50 after a 1 day share price return of 2.88%. The 1 year total shareholder return of 44.13% and 3...